Info
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
9 anni fa
#advanced, #alk, #cancer, #cancergrace, #cell, #dana, #egfr, #geoffrey, #grace, #inhibitor, #institute, #kras, #lung, #molecular, #mutation, #nonsmall, #nsclc, #oncology, #oxnard, #testing
Scopri di più
Cerca
